Please try another search
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company’s product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.
Name | Age | Since | Title |
---|---|---|---|
Peter A. Thompson | 61 | 2016 | Independent Director |
Andrew M. Scharenberg | - | - | Scientific Advisory Board Chairman |
Robert E. Conway | 67 | 2017 | Independent Director |
Mitchell H. Gold | 53 | 2015 | Executive Chairman & CEO |
James N. Topper | 59 | 2016 | Independent Director |
Paul Tumeh | - | - | Member of Scientific Advisory Board |
Manish J. Butte | - | - | Member of Scientific Advisory Board |
Xiangmin Cui | 55 | 2019 | Independent Director |
John A. Thompson | - | 2018 | Member of Scientific Advisory Board |
Anne Davidson | - | - | Member of Scientific Advisory Board |
Christopher Peetz | 44 | 2018 | Independent Director |
Vijay Kumar Kuchroo | 68 | 2019 | Member of Scientific Advisory Board |
James Welsh | - | 2018 | Member of Scientific Advisory Board |
Rafi Ahmed | - | 2018 | Member of Scientific Advisory Board |
Natasha A. Hernday | 51 | 2020 | Independent Director |
Jorn Drappa | 58 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review